Cargando…
Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum
Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454817/ https://www.ncbi.nlm.nih.gov/pubmed/37628718 http://dx.doi.org/10.3390/ijms241612537 |
_version_ | 1785096291931389952 |
---|---|
author | Doucet, Emilie J. Cortez Ghio, Sergio Barbier, Martin A. Savard, Étienne Magne, Brice Safoine, Meryem Larouche, Danielle Fradette, Julie Germain, Lucie |
author_facet | Doucet, Emilie J. Cortez Ghio, Sergio Barbier, Martin A. Savard, Étienne Magne, Brice Safoine, Meryem Larouche, Danielle Fradette, Julie Germain, Lucie |
author_sort | Doucet, Emilie J. |
collection | PubMed |
description | Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of the drawbacks associated with the use of serum, it would be advantageous to use serum-free media for the production of TESs. In a previous study, we developed a serum-free medium (Surge SFM) for the culture of keratinocytes. Herein, we tested the use of this medium, together with a commercially available serum-free medium for fibroblasts (Prime XV), to produce serum-free TESs. Our results show that serum-free TESs are macroscopically and histologically similar to skin substitutes produced with conventional serum-containing media. TESs produced with either culture media expressed keratin 14, Ki-67, transglutaminase 1, filaggrin, type I and IV collagen, and fibronectin comparably. Mechanical properties, such as contraction and tensile strength, were comparable between TESs cultured with and without serum. Serum-free TESs were also successfully grafted onto athymic mice for a six-month period. In conclusion, Surge SFM and Prime XV serum-free media could be used to produce high quality clinical-grade skin substitutes. |
format | Online Article Text |
id | pubmed-10454817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104548172023-08-26 Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum Doucet, Emilie J. Cortez Ghio, Sergio Barbier, Martin A. Savard, Étienne Magne, Brice Safoine, Meryem Larouche, Danielle Fradette, Julie Germain, Lucie Int J Mol Sci Article Tissue-engineered skin substitutes (TESs) are used as a treatment for severe burn injuries. Their production requires culturing both keratinocytes and fibroblasts. The methods to grow these cells have evolved over the years, but bovine serum is still commonly used in the culture medium. Because of the drawbacks associated with the use of serum, it would be advantageous to use serum-free media for the production of TESs. In a previous study, we developed a serum-free medium (Surge SFM) for the culture of keratinocytes. Herein, we tested the use of this medium, together with a commercially available serum-free medium for fibroblasts (Prime XV), to produce serum-free TESs. Our results show that serum-free TESs are macroscopically and histologically similar to skin substitutes produced with conventional serum-containing media. TESs produced with either culture media expressed keratin 14, Ki-67, transglutaminase 1, filaggrin, type I and IV collagen, and fibronectin comparably. Mechanical properties, such as contraction and tensile strength, were comparable between TESs cultured with and without serum. Serum-free TESs were also successfully grafted onto athymic mice for a six-month period. In conclusion, Surge SFM and Prime XV serum-free media could be used to produce high quality clinical-grade skin substitutes. MDPI 2023-08-08 /pmc/articles/PMC10454817/ /pubmed/37628718 http://dx.doi.org/10.3390/ijms241612537 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Doucet, Emilie J. Cortez Ghio, Sergio Barbier, Martin A. Savard, Étienne Magne, Brice Safoine, Meryem Larouche, Danielle Fradette, Julie Germain, Lucie Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title | Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title_full | Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title_fullStr | Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title_full_unstemmed | Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title_short | Production of Tissue-Engineered Skin Substitutes for Clinical Applications: Elimination of Serum |
title_sort | production of tissue-engineered skin substitutes for clinical applications: elimination of serum |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454817/ https://www.ncbi.nlm.nih.gov/pubmed/37628718 http://dx.doi.org/10.3390/ijms241612537 |
work_keys_str_mv | AT doucetemiliej productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT cortezghiosergio productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT barbiermartina productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT savardetienne productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT magnebrice productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT safoinemeryem productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT larouchedanielle productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT fradettejulie productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum AT germainlucie productionoftissueengineeredskinsubstitutesforclinicalapplicationseliminationofserum |